Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia.

Yamazaki M, Yamamoto N, Yarimizu J, Okabe M, Moriyama A, Furutani M, Marcus MM, Svensson TH, Harada K.

Eur Neuropsychopharmacol. 2018 May;28(5):620-629. doi: 10.1016/j.euroneuro.2018.03.003. Epub 2018 Mar 21.

2.

Neurochemical and neuropharmacological characterization of ASP2905, a novel potent selective inhibitor of the potassium channel KCNH3.

Takahashi S, Inamura K, Yarimizu J, Yamazaki M, Murai N, Ni K.

Eur J Pharmacol. 2017 Sep 5;810:26-35. doi: 10.1016/j.ejphar.2017.05.045. Epub 2017 May 25.

PMID:
28552344
3.

Characterization of two endoglucanases for the classification of the earthworm, Eisenia fetida Waki.

Akazawa S, Ikarashi Y, Yarimizu J, Yokoyama K, Kobayashi T, Nakazawa H, Ogasawara W, Morikawa Y.

Biosci Biotechnol Biochem. 2016;80(1):55-66. doi: 10.1080/09168451.2015.1075860. Epub 2015 Aug 21.

PMID:
26295166
4.

Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats.

Yamazaki M, Okabe M, Yamamoto N, Yarimizu J, Harada K.

J Pharmacol Sci. 2015 Mar;127(3):362-9. doi: 10.1016/j.jphs.2015.02.006. Epub 2015 Feb 17.

5.

ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia.

Yamazaki M, Harada K, Yamamoto N, Yarimizu J, Okabe M, Shimada T, Ni K, Matsuoka N.

Eur Neuropsychopharmacol. 2014 Oct;24(10):1698-708. doi: 10.1016/j.euroneuro.2014.07.009. Epub 2014 Jul 27.

6.

Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.

Mitani Y, Akashiba H, Saita K, Yarimizu J, Uchino H, Okabe M, Asai M, Yamasaki S, Nozawa T, Ishikawa N, Shitaka Y, Ni K, Matsuoka N.

Neuropharmacology. 2014 Apr;79:412-9. doi: 10.1016/j.neuropharm.2013.12.013. Epub 2013 Dec 25.

PMID:
24373902
7.

Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.

Nagakura A, Shitaka Y, Yarimizu J, Matsuoka N.

Eur J Pharmacol. 2013 Mar 5;703(1-3):53-61. doi: 10.1016/j.ejphar.2012.12.023. Epub 2012 Dec 28.

PMID:
23276665
8.

Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools.

Mitani Y, Yarimizu J, Akashiba H, Shitaka Y, Ni K, Matsuoka N.

J Neurochem. 2013 May;125(3):465-72. doi: 10.1111/jnc.12125. Epub 2013 Jan 8.

9.

A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.

Harada K, Nakato K, Yarimizu J, Yamazaki M, Morita M, Takahashi S, Aota M, Saita K, Doihara H, Sato Y, Yamaji T, Ni K, Matsuoka N.

Eur J Pharmacol. 2012 Jun 15;685(1-3):59-69. doi: 10.1016/j.ejphar.2012.04.013. Epub 2012 Apr 20.

PMID:
22542656
10.

Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice.

Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, Matsuoka N.

J Neurosci. 2012 Feb 8;32(6):2037-50. doi: 10.1523/JNEUROSCI.4264-11.2012.

11.

The evolutionarily conserved G protein-coupled receptor SREB2/GPR85 influences brain size, behavior, and vulnerability to schizophrenia.

Matsumoto M, Straub RE, Marenco S, Nicodemus KK, Matsumoto S, Fujikawa A, Miyoshi S, Shobo M, Takahashi S, Yarimizu J, Yuri M, Hiramoto M, Morita S, Yokota H, Sasayama T, Terai K, Yoshino M, Miyake A, Callicott JH, Egan MF, Meyer-Lindenberg A, Kempf L, Honea R, Vakkalanka RK, Takasaki J, Kamohara M, Soga T, Hiyama H, Ishii H, Matsuo A, Nishimura S, Matsuoka N, Kobori M, Matsushime H, Katoh M, Furuichi K, Weinberger DR.

Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6133-8. doi: 10.1073/pnas.0710717105. Epub 2008 Apr 14.

12.

Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.

Mihara T, Mihara K, Yarimizu J, Mitani Y, Matsuda R, Yamamoto H, Aoki S, Akahane A, Iwashita A, Matsuoka N.

J Pharmacol Exp Ther. 2007 Nov;323(2):708-19. Epub 2007 Aug 7.

PMID:
17684118
13.

A comparative study on the hydroperoxide and thiol specificity of the glutathione peroxidase family and selenoprotein P.

Takebe G, Yarimizu J, Saito Y, Hayashi T, Nakamura H, Yodoi J, Nagasawa S, Takahashi K.

J Biol Chem. 2002 Oct 25;277(43):41254-8. Epub 2002 Aug 15.

14.

Efficiency of selenocysteine incorporation in human thioredoxin reductase.

Yarimizu J, Nakamura H, Yodoi J, Takahashi K.

Antioxid Redox Signal. 2000 Winter;2(4):643-51.

PMID:
11213469

Supplemental Content

Loading ...
Support Center